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OBJECTIVES To assess whether 15-(p-[iodine-123] iodophenyl)-3-(R,S) methylpentadecanoic acid
(BMIPP) imaging can identify previous ischemic areas, BMIPP SPECT was performed in
patients with acute chest pain to compare its findings with those of technetium-99m–
tetrofosmin (tetrofosmin) SPECT and coronary angiography.
BACKGROUND Basic studies indicate that BMIPP can identify previous ischemia as reduced tracer uptake.
METHODS This study prospectively enrolled 111 consecutive patients with acute chest pain without
myocardial infarction. Tetrofosmin SPECT was performed at rest within 24 h after the last
episode of chest pain. Coronary angiography and BMIPP SPECT were also performed on
the following day.
RESULTS Sixty-four of the 87 patients with coronary stenosis or spasm showed BMIPP abnormalities
corresponding to the areas of coronary abnormalities (sensitivity 74%), whereas only 33 of
them showed perfusion abnormalities (sensitivity 38%) (p  0.001). Of the 24 patients
without coronary stenosis or spasm, 22 showed normal BMIPP SPECT (specificity 92%),
and 23 showed normal tetrofosmin SPECT (sensitivity 96%). Coronary stenosis was more
often seen in the group with abnormal tetrofosmin/abnormal BMIPP (82%) and with normal
tetrofosmin/abnormal BMIPP (69%) than in the group with normal tetrofosmin/normal
BMIPP (36%) (p  0.05). Coronary spasm was observed more often in the group with
abnormal tetrofosmin/abnormal BMIPP (83%) and with normal tetrofosmin/abnormal
BMIPP (90%) than in the group with normal tetrofosmin/normal BMIPP (27%) (p 0.05).
The extent and severity scores of tetrofosmin and BMIPP in the patients with organic
stenosis were significantly higher than those of patients with no organic stenosis or spasm
(p  0.0001).
CONCLUSIONS These data indicate that BMIPP SPECT may specifically identify previous ischemic lesions
due to coronary stenosis or spasm in patients with acute chest pain. (J Am Coll Cardiol 2001;
38:1888–94) © 2001 by the American College of Cardiology
Although an accurate diagnosis and prompt therapy are
important for patients with acute coronary syndromes, the
evaluation of acute chest pain has been difficult for many
years. An iodinated fatty acid analogue, 15-(p-[iodine-123]
iodophenyl)-3-(R,S) methylpentadecanoic acid (BMIPP)
can assess fatty acid utilization in the myocardium. Basic
studies have indicated that BMIPP imaging can identify
previous severe ischemia as areas of reduced tracer uptake
(1). Previous studies have indicated that BMIPP imaging
may identify a persistent alteration of fatty acid utilization
shortly after recovery of perfusion (2–4).
We hypothesized that BMIPP imaging shortly after chest
pain may reflect a metabolic alteration as reduced tracer
uptake. To assess whether BMIPP imaging can identify
previous ischemic areas, BMIPP single-photon emission
computed tomography (SPECT) was performed to com-
pare its findings with those of perfusion SPECT in patients
with acute chest pain.
METHODS
Patients group (Table 1). From January 1997 to Decem-
ber 2000, nearly 600 patients presenting with severe chest
pain were admitted to our hospital. This study included 111
consecutive patients (80 men and 31 women, 63  12 years
old) who received technetium-99m–tetrofosmin SPECT
(tetrofosmin) within 24 h after the last episode of chest pain.
All patients also underwent BMIPP SPECT and coronary
angiography. Patients with acute and previous myocardial
infarction (MI) or those who had undergone coronary
angioplasty or coronary artery bypass graft surgery were
excluded. Tetrofosmin SPECT was performed before cor-
onary angiography.
Study protocol. Tetrofosmin SPECT at rest and the
BMIPP study were performed within 0.7  0.5 days (1 to
24 h) and 1.7  1.5 days (1 to 5 days) after the disappear-
ance of the last episode of chest pain, respectively. The
BMIPP SPECT study was performed within two days after
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the perfusion study (98 patients on the next day and 13
patients two days later). All patients underwent coronary
angiography within 1 to 4 days (mean 2.8  1.2 days) after
the last episode of chest pain. In addition, 45 patients
without organic coronary stenosis had a spasm provocation
test (5,6). After a control angiogram was obtained, 20 g of
ergonovine maleate was selectively injected into the coro-
nary arteries, which were considered as having spasm from
the electrocardiographic (ECG) findings on hospital admis-
sion. When coronary spasm was induced and did not resolve
spontaneously, 2.5 mg of isosorbide dinitrate was infused
into the coronary artery. The provocation test was judged as
positive only when all of the following criteria were satisfied:
total or subtotal coronary occlusion, significant ST-T seg-
ment changes on the ECG and onset of chest pain.
Data analysis. The left ventricular myocardium was di-
vided into 20 segments to visually score the tracer uptake in
each SPECT study on a four-point grading system (7): 0 
normal uptake; 1  slightly reduced; 2  moderately
reduced; and 3  severely reduced. Scores of 2 and 3 were
considered to be significant. The extent score was defined as
the total number of the segments exhibiting deteriorating
uptake. The severity score was defined as the total number
of the defect score. The septal and anterior segments
correspond to the left anterior descending coronary artery
(LAD), the inferior and posterior segments correspond to
the right coronary artery (RCA) and the lateral segments
correspond to the left circumflex coronary artery (LCx). In
all patients, the areas of abnormal coronary arteries and the
reduced uptake of BMIPP were the same. Luminal stenosis
75% was defined as a significant lesion. In each patient,
the segmental uptake of tetrofosmin and BMIPP SPECT
was graded by consensus of three nuclear physicians and
cardiologists who had no previous knowledge of the clinical
data or coronary angiographic findings. This was a com-
pletely blinded method. The interobserver variability was
92%.
Statistical analysis. A comparison of proportions was
made by using the Fisher exact test. To calculate the
sensitivity and specificity, the significance of differences
between the groups was determined by using the McNemar
test. Analysis of variance with the Bonferroni correction was
used to assess the significance of differences between the
patient groups. All values are shown as the mean value 
SD. In all tests, p  0.05 was regarded as significant.
RESULTS
Clinical findings (Table 2). Abnormal ECG findings were
more often seen in the BMIPP-abnormal patients (29%)
than in the BMIPP-normal patients (13%) (p  0.05).
Abnormal ECG findings were as follows: ST-T segment
elevation (n  16, 64%), right or left bundle branch block
(n  6, 24%), paroxysmal atrial fibrillation (n  2, 8%) and
transient complete atrial ventricular block (n  1, 4%).
Reduced wall motion on echocardiogram was more often
seen in the BMIPP-abnormal patients (33%) than in the
BMIPP-normal patients (7%) (p  0.001). However, no
significant difference was observed between the BMIPP
findings and the duration of chest pain.
SPECT findings (Table 3). A regional abnormality was
seen in 34 patients (30%) on tetrofosmin SPECT at rest and
in 66 patients (59%) on BMIPP SPECT at rest (p  0.05).
In all patients, the reduced uptake of BMIPP corresponded
to the areas with abnormal coronary arteries. Thirty-four
patients with abnormal perfusion showed an abnormality
on BMIPP SPECT (group A). Of the 77 patients with
normal perfusion, 32 patients showed an abnormality on
BMIPP SPECT (group B), whereas 45 had normal BMIPP
Abbreviations and Acronyms
BMIPP  15-(p-[iodine-123] iodophenyl)-3-(R,S)
methylpentadecanoic acid
ECG  electrocardiogram or electrocardiographic
LAD  left anterior descending coronary artery
LCx  left circumflex coronary artery
MI  myocardial infarction
PET  positron emission tomography
RCA  right coronary artery
SPECT  single-photon emission computed tomography
Table 1. Study Group (n  111)
Male/female 80/31
Age in years (range) 63  12 (33–82)
History of HT/therapy 36 (33%)/30
History of DM/therapy 36 (33%)/30
History of HL/therapy 25 (23%)/15
History of smoking 36 (33%)
Previous medication 36 (33%)
Single episode 68 (61%)
20 min of chest pain 37 (34%)
ECG abnormality 25 (22%)
Wall motion abnormality (UCG, LVG) 25 (22%)
LVEF (UCG, LVG) (range) 62  9% (38–85)
75% of luminal narrowing 66 (60%)
0VD/1VD/2VD/3VD 45/33/25/8
VD involving LAD/LCx/RCA 51/36/20
Data are presented as the number (%)/number of patients or the mean value  SD
(range).
DM  diabetes mellitus; ECG  electrocardiographic; HL  hyperlipidemia;
HT  hypertension; LAD  left anterior descending coronary artery; LCx  left
circumflex coronary artery; LVEF  left ventricular ejection fraction; LVG  left
ventriculography; RCA  right coronary artery; UCG  echocardiography; 0VD/
1VD/2VD/3VD  zero-vessel/single-vessel/two-vessel/three-vessel disease; VD 
vessel disease.
Table 2. Comparison of Clinical Characteristics
BMIPP SPECT
p Value
Abnormal
(n  66)
Normal
(n  45)
ECG abnormality (n  25) 19 (29%) 6 (13%)  0.05
Reduced wall motion (n  25) 22 (33%) 3 (7%)  0.001
20 min of chest pain (n  35) 23 (35%) 14 (31%) NS
Data are presented as the number (%) of patients.
BMIPP  15-(p-[iodine-125]iodophenyl)-3-(R,S) methylpentadecanoic acid;
ECG  electrocardiographic; NS  not significant; SPECT  single-photon
emission computed tomography.
1889JACC Vol. 38, No. 7, 2001 Kawai et al.
December 2001:1888–94 BMIPP in Patients With Acute Chest Pain
SPECT images (group C). The extent and severity scores of
BMIPP were significantly higher than those of tetrofosmin
both in groups A and B.
Coronary angiographic findings (Table 4). There were 66
patients with significant organic stenosis. The spasm prov-
ocation test was performed in 45 patients without organic
coronary stenosis. Total or subtotal coronary occlusion due
to spasm, with ST-T segment changes and chest pain, was
seen in 21 patients (46%). None of the patients had spasm
with complex coronary arteries. Spontaneous spasm was
seen in four patients. The spasm was resolved in all patients
by isosorbide dinitrate injection.
Of a total of 87 patients with organic stenosis or spasm,
64 showed BMIPP abnormalities corresponding to the
areas with coronary disease (sensitivity 74%), whereas only
33 of them showed perfusion abnormalities (sensitivity
38%) (p  0.001). In contrast, 22 and 23 patients with no
organic stenosis or spasm showed no BMIPP or perfusion
abnormalities, respectively (specificity 92% and 96%, respec-
tively) (p  NS). In addition, coronary artery stenosis was
more often seen in group A (82%) and group B (69%) than
in group C (36%) (p  0.01). Coronary spasm was often
seen in group A (83%) and group B (90%), but not often in
group C (27%).
The sensitivities of BMIPP and tetrofosmin for detecting
LAD stenosis were 85% and 90%, respectively. The speci-
ficities were 80% versus 88%, respectively. The sensitivity
for detecting LCx stenosis was 50% for both BMIPP and
tetrofosmin, and the specificity was 75% for both. The
sensitivity for detecting RCA stenosis was 80% for both
BMIPP and tetrofosmin, and the specificity was 75% for
both. There were no statistically significant differences
among these values between the two tracers.
Coronary angiographic findings and SPECT scores
(Table 5). The extent and severity scores of BMIPP in the
66 patients with organic stenosis were significantly higher
than those in the 24 patients with no stenosis or spasm (p
0.01). Similarly, the extent scores of BMIPP in the 21
patients with spasm were significantly higher than those in
the patients with no stenosis or spasm (p  0.05). In
addition, in the patients with organic stenosis, the extent
and severity scores of BMIPP were significantly higher than
those of tetrofosmin (p  0.05). In contrast, the extent and
severity scores of tetrofosmin in the patients with organic
stenosis or spasm were not different from those of patients
with no stenosis or spasm. Thus, reduced uptake of BMIPP
was considered to be specifically related to the presence of
organic stenosis or spasm.
Subgroup analysis. Of the 111 patients, 29 were selected
as the subgroup that underwent perfusion SPECT within
only 6 h after the last episode of chest pain. There were 13
patients with coronary stenosis and 8 patients with coronary
spasm. The remaining eight patients had no organic stenosis
and no spasm. Six patients (21%) showed regional perfusion
abnormalities on tetrofosmin SPECT, and 14 patients
(48%) showed abnormalities on BMIPP SPECT. In pa-
tients with coronary artery stenosis or spasm, the extent and
severity scores of BMIPP were higher than those of tetro-
fosmin SPECT. The sensitivity of BMIPP SPECT to
detect coronary stenosis or spasm (66%) was significantly
higher than that of tetrofosmin SPECT (29%) (p  0.01).
The specificity was 100% for both BMIPP and tetrofosmin
SPECT.
DISCUSSION
Our data show that abnormal tracer uptake on BMIPP
images was occasionally observed even in patients who had
no perfusion abnormality at rest and in patients with acute
chest pain, particularly those with severe coronary stenosis
or spasm on coronary angiography. The BMIPP abnormal-
ities were related to wall motion and ECG abnormalities.
These data indicate that abnormal BMIPP uptake may
reflect recurrent and severe previous ischemia. Therefore,
BMIPP may be used for “ischemic memory imaging” in
patients with acute chest pain but no MI. The evaluation of
patients admitted to emergency departments with possible
ischemia and a nondiagnostic ECG (8,9) is of paramount
importance for identification of acute ischemia or infarction,
or both, as well as for risk stratification. Technetium-99m
perfusion agents have been used for this purpose. Most
reports have indicated that myocardial ischemia may be
accurately identified by perfusion studies at rest (10–12).
Table 4. Tetrofosmin and BMIPP Findings and Rates of
Disease for Three Groups
n Organic Stenosis Spasm No Abnormality
Group A 34 28/34 (82%) 5/6 (83%) 1/6
Group B 32 22/32 (69%) 9/10 (90%) 1/10
Group C 45 16/45 (36%) 7/29 (27%) 22/29
Total 111 66/111 (60%) 21/45 (46%) 24/45 (54%)
Data are presented as the number (%) of patients.
See Table 3 for definitions of groups and Table 2 for BMIPP.
Table 3. Extent and Severity Scores by Tetrofosmin and BMIPP for Three Groups
n
Extent Score Severity Score
Tetrofosmin BMIPP Tetrofosmin BMIPP
Group A 34 3.9  1.4 4.6  2.2* 7.1  4.3 10.3  6.7*
Group B 32 0.4  0.7 3.9  2.2 0.4  0.7 7.9  5.6
Group C 45 0.3  0.5 0.2  0.4 0.3  0.5 0.2  0.4
*p  0.05 vs tetrofosmin score. Data are presented as the mean value  SD.
Group A  tetrofosmin-abnormal/BMIPP-abnormal patients; group B  tetrofosmin-normal-BMIPP-abnormal patients;
and group C  tetrofosmin-normal-BMIPP-normal patients; see Table 2 for definition of BMIPP.
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Kontos et al. (13) showed that early rest perfusion imaging
was a powerful predictor of MI. In addition, this may
accurately identify patients with acute chest pain but no MI.
The present study supports the previous reports showing
abnormal perfusion at rest in patients with acute chest pain
but no evidence of MI. However, myocardial ischemia may
not be identified by rest perfusion studies alone. Other
studies indicate the importance of stress perfusion imaging
in patients with chest pain but normal perfusion at rest
(14,15). In contrast, stress perfusion imaging may not be
feasible, particularly in unstable patients. We hypothesized
that metabolic imaging at rest may add diagnostic accuracy
for identifying severe myocardial ischemia in these patients.
Value of metabolic imaging. In the normal myocardium
under aerobic conditions, 70% to 80% of the energy source
of myocardial utilization is dependent on beta-oxidization
of fatty acids. However, in ischemic conditions or in the
state of heart failure, beta-oxidization in the mitochondria is
immediately reduced (16–19). More importantly, alter-
ations of fatty acid utilization may persist in the postisch-
emic dysfunctional myocardium as “ischemic memory” (20).
11C-palmitate is a well-established positron emission tomo-
graphic (PET) tracer for providing myocardial fatty acid
utilization. However, in some countries, only a limited
number of institutions equipped with a PET camera and
cyclotron can study myocardial metabolism in vivo. In the
meantime, radio-iodinated fatty acid tracers have been
developed to probe fatty acid utilization with conventional
gamma cameras (21–23). BMIPP is one of the most
commonly used clinical agents in Japan and some European
countries because of its high extraction and retention in the
myocardium (22).
In clinical use, one of the advantages of BMIPP imaging
is the ability to visualize the damaged myocardium as areas
of reduced tracer uptake (1,22,23). Less BMIPP uptake
than perfusion SPECT is often observed in acute or old MIs
(2,6,24,25). Such discordant BMIPP uptake is often seen
early after the onset of MI (26), indicating severe metabolic
damage in the myocardium. We previously reported that the
areas of abnormal BMIPP uptake in the subacute phase
were similar to those of perfusion defects in the acute phase
of MI (27). BMIPP SPECT can also be applied to ischemic
disease without MI. In previous reports, the degree of
reduced BMIPP uptake correlated with the severity of
coronary artery stenosis (28,29). Because the flow reserve
was more limited, and ischemic attack occurred more
frequently in the coronary artery with significant stenosis
than in the coronary artery with moderate stenosis, fatty
acid utilization may decrease more in myocardial regions
supplied by coronary arteries with severe stenosis. Yamabe
et al. (30) reported BMIPP SPECT findings in subtypes of
effort angina pectoris. The detection rate of stenosed vessels
by BMIPP SPECT was more sensitive in the worsening
type than in the stable or new-onset type. In our current
study, we have not classified the subtype of unstable angina.
However, our study suggests that abnormal BMIPP uptake
may be seen in the case of recent chest pain. Thus, a new
angina episode may likely alter the BMIPP uptake. All of
these data suggest that reduced uptake of BMIPP may be
observed in the territories of coronary arteries with severe
stenosis with a recent ischemic episode (Fig. 1).
Coronary spasm. Coronary spasm is one of the important
origins of chest pain, particularly in Japan. A variant form of
angina pectoris was seen at rest with ST segment elevation,
as described by Prinzmetal et al. (31) in 1959. Patients with
vasospastic angina had left ventricular dysfunction due to
recurrent ischemia, even without coronary stenosis. In
addition, coronary vasospasm sometimes may be the cause
of sudden death (32). Therefore, an accurate diagnosis and
prompt therapy are clinically important. The diagnosis of
coronary spasm was provoked by intracoronary injection of
ergonovine maleate or acetylcholine (33–35). This type of
angina is not usually induced by exercise or dipyridamole.
Thus, a routine stress perfusion study was not able to induce
vasospastic angina.
However, because altered fatty acid utilization may be
associated with repetitive ischemic episodes, BMIPP
SPECT may hold promise for detecting coronary spasm.
The present study has shown that coronary spasm was most
often seen in patients with abnormal BMIPP uptake with
normal perfusion at rest (group B). Nakajima et al. (36) and
Watanabe et al. (37) also reported abnormal BMIPP uptake
in the territories of coronary spasm in patients with coronary
vasospasm. Our results may confirm their findings (Fig. 2).
Study limitations. Although tetrofosmin is available in
emergency departments in a cold-kit form, BMIPP is
limited because of its unavailability on an emergency basis.
A BMIPP SPECT study was obtained on the next day of
admission at earliest. In patients with mild ischemia, the
alteration of fatty acid utilization may improve, to a certain
Table 5. Single-Photon Emission Computed Tomographic Scores for Coronary
Angiographic Findings
n
Extent Score Severity Score
Tetrofosmin BMIPP Tetrofosmin BMIPP
Organic stenosis 66 1.6  1.9 3.2  2.6*† 3.2  4.2 6.8  6.9†‡
Spasm 21 1.1  2.0 2.6  2.8§ 2.0  4.3 5.3  5.0
No stenosis and no spasm 24 0.1  0.3 0.1  0.3 0.1  0.3 0.4  0.3
*p  0.05 vs. score of tetrofosmin. †p  0.01 vs. no stenosis and no spasm. ‡p  0.01 vs score for tetrofosmin. §p  0.05 vs.
no stenosis and no spasm. Data are presented as the mean value  SD.
See Table 2 for definition of BMIPP.
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degree, in the first several days after myocardial ischemia.
However, abnormal BMIPP uptake was often seen in
patients with acute chest pain despite normal perfusion, and
this result was helpful for detecting previous myocardial
ischemia. The frequency of abnormal BMIPP uptake (29%)
was relatively low, which may be due to the definition of
BMIPP uptake abnormality and patient selection. We
defined abnormal BMIPP uptake only when the score was
2 to eliminate those with equivocal or mildly reduced
uptake. We enrolled patients with a wide variety of chest
pains. When only patients with unstable angina were
selected, abnormal BMIPP uptake was more frequently
observed.
Figure 1. (A) Coronary arteriogram of a 65-year-old woman with effort
angina. Severe stenosis is seen in the left anterior descending coronary
artery (arrow). (B) Sequential tetrofosmin images. No significant abnormal
perfusion is observed on the tetrofosmin images obtained at the time of
hospital admission. However, the BMIPP images obtained on the next day
show severely reduced uptake in the apex and anteroseptal regions.
Figure 2. (A) Coronary angiogram of a 48-year-old woman with rest
angina in the early morning. Seven days later, coronary angiography shows
no significant stenosis in either coronary artery. After injection of ergono-
vine maleate into the right coronary artery, total spasm was provoked (left),
with severe chest pain and electrocardiographic changes. After isosorbide
dinitrate was injected, the spasm was completely resolved (right). (B) Series
of rest tetrofosmin perfusion and BMIPP single-photon emission com-
puted tomography images. No significant abnormal perfusion is observed
on the rest tetrofosmin images at the time of hospital admission. However,
the BMIPP images show reduced uptake in the inferior region on the next
day.
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Clinical implications. In our study, abnormal BMIPP
uptake was occasionally observed in patients with acute
chest pain. Although a tetrofosmin study can identify
patients with acute chest pain due to ischemia, rest perfu-
sion studies may often show normal findings, despite severe
coronary artery stenosis. In those patients, a stress test may
be available to identify myocardial ischemia. However, not
all patients with acute chest pain can undergo a stress test,
especially elderly people or patients with unstable angina. In
addition, even a stress test may not identify myocardial
ischemia due to coronary spasm. In patients with chest pain,
BMIPP SPECT is very useful for identifying severe isch-
emia at rest as areas of altered fatty acid utilization, before
performing coronary angiography or a provocation test.
Conclusions. Abnormal BMIPP uptake at rest was occa-
sionally seen in ischemic regions in patients with acute chest
pain. Fourteen percent of patients with acute chest pain
showed abnormal BMIPP uptake with normal perfusion at
rest. These patients were the most likely to have severe
coronary stenosis and vasospasm on angiography. The
BMIPP abnormalities were significantly related to wall
motion and ECG abnormalities. This was probably due to
prolonged impairment of fatty acid utilization, followed by
repeated ischemic attacks, which may persist after the last
episode of chest pain.
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